<DOC>
	<DOC>NCT00296257</DOC>
	<brief_summary>To compare the efficacy of SMP-114 (120 and 240 mg/d) versus placebo in terms of the percentage of patients meeting the American College of Rheumatology criteria for 20% improvement in RA (ACR20) at week 24. The study hypothesis would be to demonstrate that the use of methotrexate and SMP-114 is more efficacious than Methotrexate alone.</brief_summary>
	<brief_title>Assessment of Safety, Pharmacokinetics and Efficacy in a Combination Treatment With SMP-114</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>Male or female patients aged at least 18 years, with RA for a minimum of 6 months Has been receiving methotrexate treatment (stable for 8 weeks) Has active disease classified as ACR functional class of I, II or III Has previously discontinued DMARD therapy due to hepatic intolerance Has received any DMARD in addition to methotrexate during the 4 weeks prior to randomisation Is receiving more than 2 DMARDs in addition to methotrexate at the time of screening Is receiving or has received Gold, leflunomide or biological agents including TNF/IL1 inhibitors within the 8 weeks prior to randomisation Has previously failed 2 or more DMARDS</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
</DOC>